Clinical trial · Interventional
68Ga-N188 PET/CT Imaging in Malignancy
A Study to Evaluate 68Ga-N188 PET/CT Imaging of Nectin-4 Expression in Malignant Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Nectin-4 protein belongs to the cell adhesion factors family and has a tissue-specific expression spectrum in normal human tissues. However, Nectin-4 is overexpressed in various malignancies, especially those of epithelial origins, such as uroepithelial carcinoma, making Nectin-4 a highly specific and significant imaging target for malignancies. \[68Ga\]N188, a novel molecular probe of PET imaging agent that targets Nectin-4, can be used in the diagnosis and research of a wide variety of Nectin-4 high-expression malignancies, including bladder cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [68Ga]N188 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [68Ga]N188
- description
- Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
- interventionNames
- Drug: [68Ga]N188
Primary outcomes (2)
- measure
- The diagnostic efficacy of 68Ga-N188 PET/CT in the evaluation of malignant tumors
- timeFrame
- 1 year
- description
- Compare the standardized Uptake Value (SUV) of lesions on 68Ga-N188 and 18F-FDG PET/CT
- measure
- The diagnostic efficacy of 68Ga-N188 PET/CT in the evaluation of malignant tumors
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with confirmed or suspected cancer; * 18F-FDG PET/CT within 1 week; * Signed written informed consent. Exclusion Criteria: * Pregnant and lactating women; * Female patients plan to become pregnant within 6 months.
References
Publications (1)
- DERIVEDZhang J, Duan X, Chen X, Zhang Z, Sun H, Shou J, Zhao G, Wang J, Ma Y, Yang Y, Tian X, Shen Q, Yu W, He Z, Fan Y, Yang X. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188. J Nucl Med. 2024 May 6;65(Suppl 1):12S-18S. doi: 10.2967/jnumed.123.266830. PMID 38719240